Analysts expect Xilio Therapeutics, Inc. to report revenue of 5.01 M for Q3 26, against a range of 4.70 M to 5.32 M. The most recent reported quarter, Q2 26, came in at 18.69 M, a 42.6% beat against the 13.11 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 2.28 M | 1.72 M | 2.92 M | 8.09 M | 19.07 M | 13.69 M | 12.65 M | 18.69 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 3.84 M | 3.24 M | 4.88 M | 8.44 M | 19.19 M | 11.62 M | 8.83 M | 14.07 M | 5.32 M | 4.43 M | 4.01 M | 3.46 M | 2.45 M | 1.63 M | 2.54 M | 2.86 M | ||||||||||
| Low Estimate | 3.19 M | 2.97 M | 4.29 M | 7.49 M | 16.85 M | 10.92 M | 7.57 M | 12.15 M | 4.70 M | 4.16 M | 3.34 M | 3.06 M | 2.18 M | 1.37 M | 2.29 M | 2.43 M | ||||||||||
| Consensus Estimate | 3.51 M | 3.11 M | 4.58 M | 7.97 M | 18.02 M | 11.27 M | 8.20 M | 13.11 M | 5.01 M | 4.30 M | 3.67 M | 3.26 M | 2.31 M | 1.50 M | 2.41 M | 2.65 M |
Analysts expect Xilio Therapeutics, Inc. to report earnings per share of -0.79 for Q3 26, against a range of -0.83 to -0.75. The most recent reported quarter, Q2 26, came in at -0.33, a 42.1% beat against the -0.57 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -3.08 | -2.80 | -2.52 | -2.24 | -1.54 | 0.81 | -0.58 | -0.33 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -3.37 | -2.88 | -2.66 | -1.01 | -0.40 | -0.98 | -0.67 | -0.53 | -0.75 | -0.75 | -0.68 | -0.64 | -0.42 | -0.11 | -1.01 | -1.00 | ||||||||||
| Low Estimate | -3.97 | -3.40 | -3.08 | -1.09 | -0.46 | -1.10 | -0.73 | -0.61 | -0.83 | -0.89 | -0.76 | -0.76 | -0.46 | -0.13 | -1.21 | -1.16 | ||||||||||
| Consensus Estimate | -3.67 | -3.14 | -2.87 | -1.05 | -0.43 | -1.04 | -0.70 | -0.57 | -0.79 | -0.82 | -0.72 | -0.70 | -0.44 | -0.12 | -1.11 | -1.08 |
Pull Wall Street consensus for Xilio Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=XLO&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "XLO", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=XLO&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();